Online citations, reference lists, and bibliographies.

Association Of Angiotensin-Converting Enzyme Inhibitor Or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury

Sandeep Singh Brar, Feng Ye, Matthew T. James, Brenda R. Hemmelgarn, Scott W. Klarenbach, Neesh I Pannu
Published 2018 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Importance Patients with acute kidney injury (AKI) are at an increased long-term risk of death. Effective strategies that improve long-term outcomes in patients with AKI are unknown. Objective To evaluate whether the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) after hospital discharge is associated with better outcomes in patients with AKI. Design, Setting, and Participants This retrospective cohort study used data from the Alberta Kidney Disease Network population database to evaluate 46 253 adults 18 years or older with an episode of AKI during a hospitalization between July 1, 2008, and March 31, 2015, in Alberta, Canada. All patients who survived to hospital discharge were followed up for a minimum of 2 years. Exposures Use of an ACEI or ARB within 6 months after hospital discharge. Main Outcomes and Measures The primary outcome was mortality; secondary outcomes included hospitalization for a renal cause, end-stage renal disease (ESRD), and a composite outcome of ESRD or sustained doubling of serum creatinine concentration. An AKI was defined as a 50% increase between prehospital and peak in-hospital serum creatinine concentrations. Propensity scores were used to construct a matched-pairs cohort of patients who did and did not have a prescription for an ACEI or ARB within 6 months after hospital discharge. Results The study evaluated 46 253 adults (mean [SD] age, 68.6 [16.4] years; 24 436 [52.8%] male). Within 6 months of discharge, 22 193 (48.0%) of the participants were prescribed an ACEI or ARB. After adjustment for comorbidities, ACEI or ARB use before admission, demographics, baseline kidney function, other factors related to index hospitalization, and prior health care services, ACEI or ARB use was associated with lower mortality in patients with AKI after 2 years (adjusted hazard ratio, 0.85; 95% CI, 0.81-0.89). However, patients who received an ACEI or ARB had a higher risk of hospitalization for a renal cause (adjusted hazard ratio, 1.28; 95% CI, 1.12-1.46). No association was found between ACEI or ARB use and progression to ESRD. Conclusions and Relevance Among patients with AKI, ACEI or ARB therapy appeared to be associated with lower mortality but a higher risk of hospitalization for a renal cause. These results suggest a potential benefit of ACEI or ARB use after AKI, but cautious monitoring for renal-specific complications may be warranted.
This paper references
10.1038/ki.1996.380
Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group.
Fernando Liaño (1996)
10.1097/01.mlr.0000182534.19832.83
Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data
Hude Quan (2005)
10.1186/cc11860
Kidney function decline after a non-dialysis-requiring acute kidney injury is associated with higher long-term mortality in critically ill survivors
José António Lopes (2012)
10.1016/j.jtcvs.2007.07.021
Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement.
Peter C. Austin (2007)
10.1001/jama.2009.1322
Chronic dialysis and death among survivors of acute kidney injury requiring dialysis.
Ron Wald (2009)
Using Canadian Administrative Databases to Economic Data for Health Technology Assessments. Ottawa, Ontario: Canadian Agency for Drugs and Technologies
P Jacobs (2009)
10.2215/CJN.02440213
Association between AKI and long-term renal and cardiovascular outcomes in United States veterans.
Lakhmir S. Chawla (2014)
10.2215/CJN.06480612
Association between AKI, recovery of renal function, and long-term outcomes after hospital discharge.
Neesh I Pannu (2013)
10.1056/NEJM199209033271002
Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
Karl Swedberg (1992)
10.2215/CJN.00220605
Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey.
Orfeas Liangos (2006)
10.1681/ASN.2006010073
Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure.
Sushrut S. Waikar (2006)
10.1001/archinternmed.2010.514
The magnitude of acute serum creatinine increase after cardiac surgery and the risk of chronic kidney disease, progression of kidney disease, and death.
Areef Ishani (2011)
10.1053/j.ajkd.2008.11.034
Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis.
Steven G Coca (2009)
10.1001/jamasurg.2015.4526
Cardiovascular-Specific Mortality and Kidney Disease in Patients Undergoing Vascular Surgery.
Matthew Huber (2016)
10.1681/ASN.2009060636
Acute kidney injury associates with increased long-term mortality.
Jean-Philippe Lafrance (2010)
10.1681/ASN.2014111114
Elevated BP after AKI.
Chi-Yuan Hsu (2016)
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators
Gordon D. Murray (1993)
10.1056/NEJMoa032292
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Marc Pfeffer (2003)
10.1056/NEJM199512213332503
A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
Lars Køber (1995)
Acute Renal Failure Study Group. Epidemiology of acute renal failure: a prospective, multicenter, community-based study
F Liaño (1996)
10.1001/archinte.168.6.609
Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction.
Britt B. Newsome (2008)
10.7326/0003-4819-150-9-200905050-00006
A new equation to estimate glomerular filtration rate.
Andrew S. Levey (2009)
10.1186/1471-2369-10-30
Overview of the Alberta Kidney Disease Network
Brenda R. Hemmelgarn (2009)
10.1016/j.ahj.2008.01.031
Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
Saravanan Balamuthusamy (2008)
10.1056/NEJM199501123320203
The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction
Ettore Ambrosioni (1995)
10.1007/s40620-016-0321-6
Dialysis requirement, long-term major adverse cardiovascular events (MACE) and all-cause mortality in hospital acquired acute kidney injury (AKI): a propensity-matched cohort study
Bolanle A. Omotoso (2016)
10.1186/s12911-015-0155-5
Methods for identifying 30 chronic conditions: application to administrative data
Marcello Tonelli (2015)
10.1161/JAHA.114.000933
The Impact of Acute Kidney Injury on the Long‐term Risk of Stroke
Vincent Wu (2014)
10.1681/ASN.2013060610
Long-term risk of coronary events after AKI.
Vin-Cent Wu (2014)
10.1681/ASN.2004090740
Acute kidney injury, mortality, length of stay, and costs in hospitalized patients.
Glenn M. Chertow (2005)
Analysis of acuity trends using Resource Intensity Weights via the CIHI Portal.
Liesje Sarnecki (2009)
10.7326/0003-4819-156-8-201204170-00004
Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline
Howard A Fink (2012)
10.1097/SLA.0000000000001582
Acute and Chronic Kidney Disease and Cardiovascular Mortality After Major Surgery.
Tezcan Ozrazgat-Baslanti (2016)
10.1038/ki.2012.451
Nephrologist follow-up improves all-cause mortality of severe acute kidney injury survivors.
Ziv Harel (2013)
10.1038/ki.2009.332
Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis.
Richard L. Amdur (2009)
10.1136/bmj.e8525
Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study
Francesco Lapi (2013)
10.1016/j.amjms.2016.09.012
Acute Kidney Injury in Patients Continued on Renin‐Angiotensin System Blockers During Hospitalization☆
Numan Alabdan (2017)
10.1016/j.jvs.2016.06.052
Cardiovascular-Specific Mortality and Kidney Disease in Patients Undergoing Vascular Surgery.
Matthew Huber (2016)
The Impact of Acute Kidney Injury on the Long‐term Risk of Stroke
Vin‐CentWu (2014)
The effect of the Angiotensin-Converting-Enzyme inhibitor Zofenopril on mortality after anterior myocardial infarction.
Ettore Ambrosioni (1995)
10.1161/HYPERTENSIONAHA.109.139279
Validation of a case definition to define hypertension using administrative data.
Hude Quan (2009)
10.1038/ki.2009.289
Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease.
Lowell Lo (2009)
10.1159/000339789
KDIGO Clinical Practice Guidelines for Acute Kidney Injury
Arif Khwaja (2012)
10.1053/j.ajkd.2015.10.019
Acute Kidney Injury Recovery Pattern and Subsequent Risk of CKD: An Analysis of Veterans Health Administration Data.
Michael Heung (2016)
10.1056/NEJM199209033271001
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.
Marc Pfeffer (1992)
10.1093/ndt/gfv346
Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial
Sunil Bhandari (2016)
10.1161/01.CIR.97.18.1837
Prediction of coronary heart disease using risk factor categories.
Peter W. F. Wilson (1998)
10.1681/ASN.2007080837
Acute kidney injury increases risk of ESRD among elderly.
Areef Ishani (2009)
10.1002/pst.433
Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies
Peter C. Austin (2011)



This paper is referenced by
10.1016/j.jhep.2020.02.015
Acute kidney injury in cirrhosis: An immediate threat but also a ticking time bomb.
Claire Francoz (2020)
10.1038/s41581-019-0247-z
Long-term outcomes of acute kidney injury and strategies for improved care
Matthew T. James (2020)
10.1007/s11897-020-00452-4
Iatrogenic Decompensated Heart Failure
Patrick Tran (2020)
10.2215/cjn.13801119
Renin-Angiotensin System Blockade after Acute Kidney Injury: The Plot Thickens.
Steven Menez (2019)
10.1016/j.xkme.2019.12.007
ACE Inhibitor/Angiotensin Receptor Blocker Use Patterns in Advanced CKD and Risk of Kidney Failure and Death
Nayan Arora (2020)
10.1016/j.amjmed.2020.03.037
Longer predialysis ACEi/ARB utilization is associated with reduced postdialysis mortality.
Elvira O. Gosmanova (2020)
10.2215/CJN.14021118
Stopping RAS Inhibitors to Minimize AKI: More Harm than Good?
Charles R V Tomson (2019)
10.1159/000505893
Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Acute Kidney Disease after an Episode of AKI: A Multicenter Prospective Cohort Study
Abigail Hines (2020)
10.1016/J.CJCA.2019.06.032
New Insights Into Mechanisms of Acute Kidney Injury in Heart Disease.
Sriram Sriperumbuduri (2019)
10.1007/978-981-15-1108-0_13
Prophylaxis and Management of Acute Kidney Injury
Yasuhiro Komatsu (2020)
10.1186/s13054-019-2447-0
Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial
Mathilde Scarton (2019)
10.1159/000505896
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers after Acute Kidney Injury: Friend, Foe, or Acquaintance?
Steven G Coca (2020)
10.1007/s00092-019-2284-0
Akutes Nierenversagen: Bessere Prognose durch Hemmstoffe des Renin-Angiotensin-Systems?
Beate Schumacher (2019)
10.2215/CJN.05800519
Renin-Angiotensin System Blockade after Acute Kidney Injury (AKI) and Risk of Recurrent AKI.
Chi-Yuan Hsu (2019)
10.1007/978-981-15-1108-0
Acute Kidney Injury and Regenerative Medicine
Yoshio Terada (2020)
10.1177/2054358119880519
Roadblocks and Opportunities to the Implementation of Novel Therapies for Acute Kidney Injury: A Narrative Review
Paraish S. Misra (2019)
10.3390/jcm8030395
Medication-Related Factors and Hospital Readmission in Older Adults with Chronic Kidney Disease
Wubshet Hailu Tesfaye (2019)
10.1016/j.mayocp.2019.09.014
How Do We Navigate the Complexities Surrounding the Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Chronic Kidney Disease?
Sunil Bhandari Chadburn (2019)
10.1001/jamainternmed.2018.4757
Use of Renin Angiotensin System Blockers After Acute Kidney Injury: Balancing Tradeoffs.
Robert J. Alpern (2018)
10.1136/heartjnl-2018-314158
Change in renal function associated with drug treatment in heart failure: national guidance
Andrew L Clark (2019)
10.1159/000499940
Is the Renin-Angiotensin-Aldosterone System Good for the Kidney in Acute Settings?
Emmanuel Dudoignon (2019)
10.1016/j.biopha.2018.12.018
Fiend and friend in the renin angiotensin system: An insight on acute kidney injury.
Nisha Nandlal Sharma (2019)
10.1001/jamainternmed.2019.6390
Post-Acute Kidney Injury Proteinuria and Subsequent Kidney Disease Progression: The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) Study.
Chi-Yuan Hsu (2020)
Semantic Scholar Logo Some data provided by SemanticScholar